News und Analysen

Novavax (NASDAQ: NVAX) fell behind in the original coronavirus vaccine race as rivals Pfizer and Moderna brought their products to market. The biotech launched its vaccine a year-and-a-half later in

Shares of Ardelyx (NASDAQ: ARDX) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this

Shares of Sharecare (NASDAQ: SHCR) were up more than 26% as of 2 p.m. ET on Wednesday after the digital healthcare company said it had received a proposal from a private equity firm to buy the

Medical device giant Abbott Laboratories (NYSE: ABT) hasn't performed well in the past year. The company has had to deal with several issues that affected its results and its public image, notably

Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron

Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) were up more than 15% as of 11 a.m. on Tuesday after Express Scripts said it will give certain clients access to Lexicon's drug Inpefa. The healthcar

Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in

Shares of Scilex Holdings (NASDAQ: SCLX) were up around 14% as of 2:30 p.m. ET on Monday. The healthcare stock is still down more than 55% this year.

Scilex makes non-opioid pain management products

Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year.

Tango is a clinical-stage biotech that focuses on

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.

Three Motley Fool contributors think they've picked some stocks

Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the

There are excellent reasons to invest in dividend stocks beyond their regular payouts. Growing a dividend requires companies to deliver solid financial results regularly, and the longer a

Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID

Shares of Coherus BioSciences (NASDAQ: CHRS) rose 9.4% on Thursday after the biotech resubmitted a biologic license application (BLA) supplement for a key product to the U.S. Food and Drug

Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite

UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. It's already a top health insurer in the U.S., but that doesn't mean the company isn't working to be even

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Meet the

A fairly uninspiring set of quarterly results pushed AngioDynamics (NASDAQ: ANGO) stock down in value on Wednesday. The medical device and technology company saw its share price dip by almost 3% on

High-yield dividend stocks are a powerful way to boost a portfolio's annual performance. By reinvesting the dividend and regularly buying more shares, these stocks can produce impressive returns

If you're investing in a dividend stock, there's more than just the yield and the payout ratio to consider. It's also important to look at dividend increases -- whether the company has been making

Wall Street analysts are quite bullish right now on gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) -- expecting, on average, the stock to soar 167% in the coming 12 months. Yet

Pfizer (NYSE: PFE) sells a wide variety of medicines across treatment areas such as autoimmune diseases and oncology. But it probably is most known for its leading coronavirus vaccine, which helped

Biotech stocks offer us a wide range of investing opportunities. You could buy shares of a research stage company and bet on a potential game-changing product that may launch several years from now